A new direction for cytomegalovirus prophylaxis among transplant recipients: Benefits and nonviral outcomes of letermovir use as primary CMV prophylaxis
aDepartment of Pharmacy, Northwestern Medicine, Chicago, Illinois, USA
bDivision of Infectious Disease, Department of Medicine, University of Montreal Hospital Center, Montreal, Quebec, Canada
cDivision of Infectious Disease, Department of Medicine, Inova Medical Group, Falls Church, Virginia, USA
Correspondence to W. Justin Moore, Northwestern Medicine, Chicago, IL United States. Tel: +1 804 840 2340; e-mail: [email protected]
Comments (0)